76 related articles for article (PubMed ID: 16870259)
1. Proteasome inhibitor MG-132 induces dopaminergic degeneration in cell culture and animal models.
Sun F; Anantharam V; Zhang D; Latchoumycandane C; Kanthasamy A; Kanthasamy AG
Neurotoxicology; 2006 Sep; 27(5):807-15. PubMed ID: 16870259
[TBL] [Abstract][Full Text] [Related]
2. Nigral degeneration with inclusion body formation and behavioral changes in rats after proteasomal inhibition.
Niu C; Mei J; Pan Q; Fu X
Stereotact Funct Neurosurg; 2009; 87(2):69-81. PubMed ID: 19223692
[TBL] [Abstract][Full Text] [Related]
3. The activation sequence of cellular protein handling systems after proteasomal inhibition in dopaminergic cells.
Xiong R; Siegel D; Ross D
Chem Biol Interact; 2013 Jul; 204(2):116-24. PubMed ID: 23684743
[TBL] [Abstract][Full Text] [Related]
4. Repetitive transcranial magnetic stimulation for treatment of lactacystin-induced Parkinsonian rat model.
Ba M; Ma G; Ren C; Sun X; Kong M
Oncotarget; 2017 Aug; 8(31):50921-50929. PubMed ID: 28881616
[TBL] [Abstract][Full Text] [Related]
5. In-vitro Approaches to Investigate the Detrimental Effect of Light on Dopaminergic Neurons.
Fasciani I; Petragnano F; Bono F; Aloisi G; Mutti V; Pardini C; Carli M; Scarselli M; Vaglini F; Angelucci A; Fiorentini C; Lozzi L; Missale C; Maggio R; Rossi M
Neuroscience; 2024 Apr; 544():104-116. PubMed ID: 38244669
[TBL] [Abstract][Full Text] [Related]
6. Proteasome inhibitors MG132 and lactacystin hyperphosphorylate HSF1 and induce hsp70 and hsp27 expression.
Kim D; Kim SH; Li GC
Biochem Biophys Res Commun; 1999 Jan; 254(1):264-8. PubMed ID: 9920768
[TBL] [Abstract][Full Text] [Related]
7. Neuropathogenesis-on-chips for neurodegenerative diseases.
Amartumur S; Nguyen H; Huynh T; Kim TS; Woo RS; Oh E; Kim KK; Lee LP; Heo C
Nat Commun; 2024 Mar; 15(1):2219. PubMed ID: 38472255
[TBL] [Abstract][Full Text] [Related]
8. Unravelling the Parkinson's puzzle, from medications and surgery to stem cells and genes: a comprehensive review of current and future management strategies.
Chandrababu K; Radhakrishnan V; Anjana AS; Rajan R; Sivan U; Krishnan S; Baby Chakrapani PS
Exp Brain Res; 2024 Jan; 242(1):1-23. PubMed ID: 38015243
[TBL] [Abstract][Full Text] [Related]
9. Identification of the bacterial metabolite aerugine as potential trigger of human dopaminergic neurodegeneration.
Ückert AK; Rütschlin S; Gutbier S; Wörz NC; Miah MR; Martins AC; Hauer I; Holzer AK; Meyburg B; Mix AK; Hauck C; Aschner M; Böttcher T; Leist M
Environ Int; 2023 Oct; 180():108229. PubMed ID: 37797477
[TBL] [Abstract][Full Text] [Related]
10. Cerebrospinal Fluid Metabolome in Parkinson's Disease and Multiple System Atrophy.
Kwon DH; Hwang JS; Kim SG; Jang YE; Shin TH; Lee G
Int J Mol Sci; 2022 Feb; 23(3):. PubMed ID: 35163800
[TBL] [Abstract][Full Text] [Related]
11. Effects of Cholesterol in Stress-Related Neuronal Death-A Statistical Analysis Perspective.
Dayeh MA; Livadiotis G; Aminian F; Cheng KH; Roberts JL; Viswasam N; Elaydi S
Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32326309
[TBL] [Abstract][Full Text] [Related]
12. Neurotoxicity of pesticides.
Richardson JR; Fitsanakis V; Westerink RHS; Kanthasamy AG
Acta Neuropathol; 2019 Sep; 138(3):343-362. PubMed ID: 31197504
[TBL] [Abstract][Full Text] [Related]
13. Hapln2 in Neurological Diseases and Its Potential as Therapeutic Target.
Wang Q; Wang C; Ji B; Zhou J; Yang C; Chen J
Front Aging Neurosci; 2019; 11():60. PubMed ID: 30949044
[TBL] [Abstract][Full Text] [Related]
14. Mechanistic Interplay Between Autophagy and Apoptotic Signaling in Endosulfan-Induced Dopaminergic Neurotoxicity: Relevance to the Adverse Outcome Pathway in Pesticide Neurotoxicity.
Song C; Charli A; Luo J; Riaz Z; Jin H; Anantharam V; Kanthasamy A; Kanthasamy AG
Toxicol Sci; 2019 Jun; 169(2):333-352. PubMed ID: 30796443
[TBL] [Abstract][Full Text] [Related]
15. Longitudinal monoaminergic PET imaging of chronic proteasome inhibition in minipigs.
Lillethorup TP; Glud AN; Alstrup AKO; Noer O; Nielsen EHT; Schacht AC; Landeck N; Kirik D; Orlowski D; Sørensen JCH; Doudet DJ; Landau AM
Sci Rep; 2018 Oct; 8(1):15715. PubMed ID: 30356172
[TBL] [Abstract][Full Text] [Related]
16. Parkinson's disease: experimental models and reality.
Jiang P; Dickson DW
Acta Neuropathol; 2018 Jan; 135(1):13-32. PubMed ID: 29151169
[TBL] [Abstract][Full Text] [Related]
17.
Gleixner AM; Hutchison DF; Sannino S; Bhatia TN; Leak LC; Flaherty PT; Wipf P; Brodsky JL; Leak RK
Mol Pharmacol; 2017 Nov; 92(5):564-575. PubMed ID: 28830914
[No Abstract] [Full Text] [Related]
18. The Proteasome Inhibition Model of Parkinson's Disease.
Bentea E; Verbruggen L; Massie A
J Parkinsons Dis; 2017; 7(1):31-63. PubMed ID: 27802243
[TBL] [Abstract][Full Text] [Related]
19. Elevated Hapln2 Expression Contributes to Protein Aggregation and Neurodegeneration in an Animal Model of Parkinson's Disease.
Wang Q; Zhou Q; Zhang S; Shao W; Yin Y; Li Y; Hou J; Zhang X; Guo Y; Wang X; Gu X; Zhou J
Front Aging Neurosci; 2016; 8():197. PubMed ID: 27601993
[TBL] [Abstract][Full Text] [Related]
20. Apigenin Reduces Proteasome Inhibition-Induced Neuronal Apoptosis by Suppressing the Cell Death Process.
Kim A; Nam YJ; Lee MS; Shin YK; Sohn DS; Lee CS
Neurochem Res; 2016 Nov; 41(11):2969-2980. PubMed ID: 27473386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
